display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced RCC (mRCC) - 1st line (L1)
metastatic/advanced RCC (mRCC) - 1st line (L1)
everolimus
lenvatinib plus everolimus KEYNOTE-581/CLEAR ...

Study type: